New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2013
19:03 EDTCTICCell Therapeutics announces N.I.C.E. draft guidance on Pixuvri
Cell Therapeutics announced that the National Institute for Health and Care Excellence, a non-departmental public body of the Department of Health in the United Kingdom, issued draft guidance on Pixuvri as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. The draft guidance does not recommend funding of Pixuvri by the U.K.'s National Health Service and requests that consultees, including CTI, healthcare professionals and members of the public, comment on the preliminary recommendations, which are available to view on the NICE website. The consultation will be open until May 1.
News For CTIC From The Last 14 Days
Check below for free stories on CTIC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 7, 2014
09:08 EDTCTICOn The Fly: Pre-market Movers
Subscribe for More Information
05:44 EDTCTICCTI BioPharma announces Pacritinib granted fast track designation by FDA
CTI BioPharma announced that pacritinib has been granted Fast Track designation by the FDA for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy. Pacritinib is an oral tyrosine kinase inhibitor with dual activity against JAK2 and FLT3. The drug candidate is currently being evaluated in two Phase 3 clinical trials, known as the PERSIST program, for patients with myelofibrosis.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use